Baxter collaborated with Miromatrix to help advance bioengineered replacement organs for patients suffering from acute liver failure
Miromatrix’s liver replacement therapy, miroliverELAP combines Miromatrix’s single-use bioengineered liver with Baxter’s PrisMax system. An IND application for miroliverELAP was submitted to the US FDA in Nov 2022 and aimed to begin a P-I clinical trial using miroliverELAP to treat patients with ALF
MiroliverELAP provides external support to the patient’s native liver as a bridge-to-transplant or bridge-to-recovery, potentially helping to avoid a liver transplant while Baxter’s PrisMax system helps to deliver continuous renal replacement therapy and other therapies
Ref: Businesswire | Image: Miromatrix
Related News:- Baxter to Acquire Hillrom for ~$10.5B
